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Overview of renal transplant rejection
Renal transplantation is an effective treatment option 
for patients with end-stage renal disease. Since the first 
successful renal transplant, which was carried out be-
tween identical twins in 1954 in the United States [1], this 
procedure has been widely performed in many Western 
and Eastern countries. In Korea, the first successful renal 
transplant occurred in 1969, and in the past six years, more 
than 15,000 renal transplants have been performed [2].
The concept of rejection was recognized in the early 
1900s by Alexis Carrell, who coined the term ‘biologic in-
compatibility’ [1]. Rejection is an immunologic reaction 
to donor antigens that are recognized by a recipient’s im-
mune system. This continues to present a major obstacle 
to long-term allograft survival [3], despite progressive im-
provements in surgical techniques, advances in immu-
nology, and the introduction of new immunosuppressive 
drugs. Renal allograft biopsy is a direct and confirmative 
tool for the diagnosis of rejection that can be used to as-
sess both the type and degree of rejection.
Pathologic changes associated with acute and chronic 
renal allograft rejections have been reported since the 
late 1960s [4-7]. However, no standardized classification 
system was proposed until 1991, when a group of 28 re-
nal pathologists, nephrologists, and transplant surgeons 
gathered in Banff, Canada, and outlined international 
standards for the definition and grading of transplant 
rejection [8]. After the first ‘Banff Working Classifica-
tion of Kidney Transplant Pathology’ report, successive 
biannual meetings have been held, with the recent 2019 
meeting taking place in Pittsburgh [9-18], and the results 
have been published as meeting reports. In this review, 
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rejections, up-to-date revisions and pitfalls of the Banff 
Classification of Allograft Pathology [8-18], and future 
perspectives.
Pathology of renal allograft rejection
Rejection pathology can be observed in all four compo-
nents of the kidney—the glomeruli, tubules, interstitium, 
and vessels—either individually or in combination. In 
most rejection cases, renal allograft biopsy shows mor-
phologic injuries resulting from predominantly cellular 
or antibody-mediated mechanisms. Depending on the 
time post-transplantation and rejection activity, this con-
dition can be classified as either acute/active or chronic. 
However, acute and chronic changes can exist within 
the same biopsy [19]. Importantly, although acute and 
chronic are clinical terms suggesting the time of onset of 
a disease, here, this classification reflects activity or inac-
tivity, rather than time of biopsy. Thus, active lesions may 
appear late, and chronic lesions may develop early dur-
ing the post-transplant period.
Interpretation of allograft histology should consider 
recipient as well as donor factors. For example, older 
donors may have significant glomerulosclerosis and tu-
bulointerstitial fibrosis, and kidneys from brain-dead 
donors may have ischemic changes. Rarely, donor-trans-
mitted disease may be observed in time-zero or early bi-
opsies. In this case, an implantation or zero-hour biopsy 
may be useful as a reference. In late-transplant biopsies, 
the possibility of recurrent or de novo development of 
glomerular, metabolic, or systemic diseases should be 
considered. Drug toxicity and infections may also de-
velop at any time post-transplant. If a graft biopsy is ob-
tained late, graft histology is likely to show mixed features 
that are attributable to more than one cause.
Renal allograft biopsy samples can be analyzed by light, 
immunofluorescence, and electron microscopy. Among 
these, the features that are assessed by light microscopy 
are essential and the most important. Immunofluores-
cence microscopy or immunohistochemistry is needed to 
detect footprints of antibody binding and immune com-
plexes, whereas electron microscopy is used for the de-
tection of chronic antibody-mediated rejection (ABMR). 
Rejection pathology can be described according to activ-
ity or the histologic component involved, as described 
below.
Rejection pathology according to activity
Acute (active) rejection
Acute (active) rejection is characterized by tubulitis, 
interstitial inflammation, glomerulitis, peritubular capil-
laritis, and arteritis.
Chronic rejection
Chronic rejection is characterized by tubular atrophy, 
interstitial fibrosis, transplant glomerulopathy, multi-
layering of peritubular capillary (PTC) basement mem-
branes, and transplant arteriopathy.
Rejection pathology according to histologic component
Glomerulus
Glomerulitis
Glomerulitis is characterized by endothelial enlarge-
ment and inflammatory cell infiltration, often resulting 
in capillary luminal narrowing and destruction (Fig. 1). 
The infiltrating inflammatory cells may be T cells, mono-
cytes, or neutrophils. This can be observed in the context 
of ABMR, and it is believed to be caused by endothelial 
injury that is mainly directed to human leukocyte antigen 
(HLA).
Inflammatory cells may also be present in non-ABMR 
conditions, such as acute T cell-mediated rejection 
Figure 1. A glomerulus shows hypercellularity, with endothelial 
swelling (arrow) and inflammatory cell infiltration (arrowhead), as 
detected by hematoxylin and eosin (H&E, ×200) staining.
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(TCMR) and glomerulonephritis. For example, glomeru-
lar hypercellularity, which is referred to as ‘endocapillary 
hypercellularity’, is sometimes observed in immuno-
globulin (Ig)A nephropathy that develops after trans-
plantation [20]. This can therefore produce a diagnostic 
dilemma, particularly when the presence of concurrent 
ABMR is suspected.
Mesangiolysis
Mesangiolysis results from dissolution of the mesangial 
matrix and manifests as a pale area after periodic acid-
Schiff (PAS) staining. It may be present in the context of 
ABMR, but may also occur with non-rejection conditions 
that are associated with endothelial or mesangial cell in-
jury. The most common condition in which this occurs is 
thrombotic microangiopathy (TMA), but mesangiolysis 
may also be present in other glomerular diseases.
Mesangial matrix increase
An increased mesangial matrix is defined as a matrix 
that exceeds the width of two mesangial cells in two ad-
jacent glomerular lobules (Fig. 2). The mesangial matrix 
may be increased in association with chronic rejection; 
however, this feature is entirely nonspecific. In practice, 
increased mesangial matrix, along with mesangial hyper-
cellularity, is frequently associated with IgA nephropathy 
or diabetic nephropathy post-transplant.
TMA
TMA is characterized by microthrombi, glomerular 
subendothelial electron-lucent widening, deposition of 
fluffy material, and the formation of a new subendothe-
lial basement membrane (Fig. 3). This can be observed in 
the context of active ABMR related to endothelial injury. 
However, TMA may be present in other non-rejection 
conditions, such as recurrent atypical hemolytic uremic 
syndrome or drug-related conditions. In particular, calci-
neurin inhibitors, such as cyclosporine A and tacrolimus, 
induce dose-dependent endothelial dysfunction [21,22], 
and sirolimus, administered either alone or in combina-
tion with cyclosporine, can cause TMA [23]. Therefore, 
differential diagnosis may not be possible without both 
clinical history and laboratory data.
Transplant glomerulopathy
Transplant glomerulopathy is characterized by dou-
bling or even multilayering of the glomerular basement 
membrane (GBM) (Fig. 4). GBM doubling is best detect-
ed with PAS or methenamine silver methods, but is only 
demonstrable by electron microscopy in the early stages 
of development. Transplant glomerulopathy may be seen 
in chronic ABMR that is caused by repeated endothelial 
injury and repair. Similar features can be present in other 
conditions, such as TMA and membranoproliferative glo-
merulonephritis associated with hepatitis C viral infec-
tion. However, glomerular immune complex deposition 
is a feature of membranoproliferative glomerulonephri-
Figure 2. Periodic acid-Schiff stain shows mesangial expansion (ar-
row), with increased mesangial cells and matrix. Afferent arteriolar 
hyalinosis (arrowhead) is also present (×200).
Figure 3. Several glomerular capillary lumens showing microaneu-
rysmal dilatation; these lumens are filled with pinkish fibrinous ma-
terial (arrow) as detected by periodic acid-Schiff staining (×400).
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Acute tubular injury may be a sign of active ABMR if it is 
present in the absence of other known causes. Proximal 
tubular epithelial cells are most commonly affected, and 
flattening of the cytoplasm, loss of brush borders, and lu-
minal dilatation can be observed (Fig. 5). Overt necrosis 
is not common, and intratubular microcalcification may 
be present.
Overt tubular necrosis is also often associated with 
polyomavirus infection. In this case, necrotic tubular 
cells may have intranuclear viral inclusions. In addition, 
acute tubular injury may be a sign of ischemia or drug 
toxicity. Therefore, observation of other clinical or im-
munologic features supportive of ABMR is required to 
confirm diagnosis.
Tubulitis
Tubulitis is a feature of acute and chronic active TCMR. 
It is characterized by the presence of inflammatory cells 
between tubular epithelial cells (Fig. 6). In acute TCMR, 
tubulitis is present in non-severely atrophic tubules. In 
chronic active TCMR, tubulitis involves both atrophic 
and non-atrophic tubules. The inflammatory cells pres-
ent in tubulitis are most commonly lymphocytes and 
monocytes, but plasma cells may also be present.
Tubulitis can further result from infections and drug-
induced interstitial nephritis, and it occasionally occurs 
in association with glomerulonephritis. Neutrophils may 
*
Figure 5. Tubules show flattening of the cytoplasm and luminal 
dilatation, associated with interstitial edema, mild interstitial inflam-
mation (arrow), and peritubular capillaritis (asterisk) (periodic acid-
Schiff staining, ×200).
Figure 6. Mononuclear cells (arrow) are present between tubular 




Figure 4. (A) Thickening and doubling 
of the glomerular basement membrane 
(arrow) is detected in transplant glo-
merulopathy (methenamine silver stain-
ing, ×200). (B) Subendothelial electron-
lucent widening and new basement 
membrane formation can be seen.
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be dominant in bacterial infection, often with intralumi-
nal neutrophilic abscess, and plasma cells are sometimes 
present in infiltrate from polyomavirus-associated in-
terstitial nephritis. However, distinction between drug-
induced interstitial nephritis and TCMR is not always 
possible.
Tubular atrophy
Tubular atrophy is a non-specific feature of chronic 
rejections and non-rejections. This is characterized by a 
> 50% narrowing of the tubular diameter or thickening 
of the basement membrane (Fig. 7). In some cases, this 
condition resembles endocrine glands without thicken-
ing of basement membrane. Severity of tubular atrophy 
is divided into three tiers (mild, moderate, and severe) 
based on the percentage of atrophic tubules (< 25%, 25% 
to 50%, and > 50%), and atrophic tubules are frequently 
replaced by interstitial fibrosis.
Interstitium
Interstitial edema
Interstitial edema is characterized by the presence of 
widened and lightly stained interstitium due to the accu-
mulation of tissue fluid (Fig. 8). In acute TCMR, inflam-
matory cells are present in the edematous stroma.
Interstitial inflammation
Interstitial inflammation is a feature of acute and 
chronic active TCMR. In acute TCMR, inflammatory cell 
infiltration is present in the edematous stroma, associ-
ated with tubulitis of non-severely atrophic tubules (Fig. 
8). In chronic active TCMR, inflammatory cells are found 
in both the edematous and fibrotic stroma, and this is 
accompanied by tubulitis of atrophic and non-atrophic 
tubules. The infiltrating cells are most often lympho-
cytes and monocytes, but plasma cells, neutrophils, or 
eosinophils can also be present. Immunohistochemistry 
has shown that T cells tend to infiltrate diffusely or in 
scattered patterns, whereas B cells are often aggregated. 
Inflammatory cells may also be present in Bowman’s 
capsule, resulting in Bowman’s capsulitis [24] in acute 
TCMR.
Notably, interstitial inflammation itself is a non-specific 
finding. Minimal inflammation may result from acute 
tubular injury and drug toxicity. In addition, interstitial 
inflammation can be present in drug-induced interstitial 
nephritis and polyomavirus-associated interstitial ne-
phritis.
Interstitial hemorrhage
Interstitial hemorrhage occurs when extravasated red 
blood cells are present in the interstitium (Fig. 9). This 
may be seen in, but is not pathognomonic of, active 
ABMR or acute TCMR.
Interstitial fibrosis
In interstitial fibrosis, collagen fibrils and extracellular 
Figure 7. Periodic acid-Schiff staining shows reduced tubular sizes 
and thickening of tubular basement membranes (arrows), compat-
ible with tubular atrophy (×40).
*
Figure 8. Acute tubular injury, interstitial edema (asterisk), minimal 
interstitial inflammation and peritubular capillaritis are observed 
(periodic acid-Schiff staining, ×100).
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matrix components are increased in the interstitium (Fig. 
10). This can be observed in both rejection and non-re-
jection conditions. In the context of chronic active TCMR, 
inflammatory cell infiltration may be seen in fibrotic in-




Peritubular capillaritis is characterized by the presence 
of both mononuclear and polymorphonuclear inflam-
matory cells in an often-dilated PTC lumen (Fig. 11). 
This condition is associated with active or chronic active 
ABMR. Although inflammatory cells may also be found in 
the PTC lumen in acute TCMR or other conditions, infil-
tration is usually mild and limited to areas of tubulointer-
stitial inflammation.
Arteritis
Arteritis can result from active ABMR and acute TCMR. 
Intimal arteritis is characterized by the presence of 
inflammatory cells, mainly T lymphocytes and macro-
phages, in the intima, often with lifting off endothelial 
cells (Fig. 12). In severe cases, transmural inflammation 
involving arterial media develops, accompanied by fibri-
noid necrosis. If the intima does not fully recover to its 
original state, for example during chronic rejection, the 
intima will become thickened, forming neointima, which 
can trap inflammatory cells.
Multilayering of PTC basement membranes (PTCBML)
PTCBML is associated with chronic ABMR. This condi-
tion is usually detected by electron microscopy (Fig. 13), 
although thickening of capillary basement membranes 
can be seen by light microscopy in severe cases [25]. Sim-
ilar to transplant glomerulopathy, PTCBML is believed to 
be the sequela of repeated PTC injury and repair, result-
ing in repeated basement membrane formation with pro-
gressive narrowing of the lumen. Severe PTCBML with 
Figure 10. The interstitium is widened by increased extracellular 
matrix, including collagen fibrils, in interstitial fibrosis (periodic acid-
Schiff staining, ×40).
Figure 11. Inflammatory cells (arrowheads) are present in peritu-
bular capillaries (PTCs), and the tubules are relatively intact (H&E 
staining, ×400).
*
Figure 9. Extravasated red blood cells (asterisk) are found in the in-
terstitium during interstitial hemorrhage; acute tubular injury is also 
present (H&E staining, ×100).
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circumferential involvement is more likely to be caused 
by alloimmune injury, whereas low-grade basement 
membrane layering with focal involvement is a frequent 
finding in non-rejections.
Transplant arteriopathy
Transplant arteriopathy can be caused by chronic 
ABMR and TCMR. In transplant arteriopathy, the arterial 
intima is thickened, forming a neointima (Fig. 14), which 
often contains foamy macrophages and lymphocytes. 
However, unlike fibroelastosis of hypertensive arterio-
sclerosis, elastic lamellation is not seen in transplant 
arteriopathy-associated neointima.
PTC C4d staining
Complement C4d is a product of comple ment activa-
tion, and linear, circumferential staining of this molecule 
in PTCs and the vasa recta (Fig. 15) can be used as a 
marker for ABMR. C4d binds to the endothelial surface 
via  covalent bonding even after antibody has disap-
peared; therefore, it serves as a footprint for the antigen-
antibody reaction. Glomerular C4d staining is more 
frequently observed in C4d-positive cases than in C4d-
Figure 14. Disruption of the internal elastic lamina (arrowheads) is 




Figure 13. Multilayering of capillary basement membranes (aster-
isks) is observed in two peritubular capillaries by electron micros-
copy.
Figure 15. C4d staining is present in peritubular capillaries (arrows) 
and glomerular capillary walls (arrowheads), as detected by immu-
nohistochemistry (×200).
Figure 12. Inflammatory cells (arrows) infiltrate the intima in intimal 
arteritis, involving more than 50% of its circumference (H&E stain-
ing, ×200).
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negative cases, although it has no clinical significance.
Evaluation of C4d positivity varies according to staining 
method. Immunofluorescence is more sensitive than im-
munohistochemical methods, and the staining intensity 
may also be affected by the length of time C4d was pres-
ent at the antigen-antibody reaction site [26]. ABMR can 
occur without C4d positivity (C4d-negative ABMR), and 
C4d staining may be positive without rejection in ABO 
incompatible grafts.
Banff classification
The Banff classification for transplant pathology, which 
was first published in 1993 [8], has several important ad-
vantages: 1) It helps facilitate effective communication 
among transplant physicians, surgeons, and pathologists; 
2) it is useful for assessing the effects of new immunosup-
pressive drugs in international multicenter clinical trials; 
and 3) it can be used for transplant research in addition 
to diagnosis.
The most recent Banff classification has six catego-
ries (Table 1) [27]. Rejection categories are Category 2 
(antibody-mediated changes), Category 3 (borderline for 
acute TCMR), and Category 4 (TCMR). Before describing 
the different types of rejection, the basic requirements for 
biopsy interpretation and histologic scoring systems will 
be outlined.
Specimen adequacy
Requirements for specimen adequacy were established 
in Banff 1991 and Banff 1997. Currently, the presence of 
seven glomeruli with one artery is marginal, and ≥ 10 
glomeruli with at least two arteries is considered adequate 
for numeric coding [9]. At least seven slides, three stained 
with hematoxylin and eosin (H&E), three stained with PAS, 
and one stained with trichrome stain should be evaluated.
Quantitative criteria for acute and chronic changes
Quantitative criteria for classifying acute and chronic 
changes in glomeruli, tubules, interstitium, and arter-
ies/arterioles were established in 1991 and 1997 [9]. Only 
cortical tubules and interstitium are considered for eval-
uation.
Characters representing glomerular changes are ‘g’ 
(glomerulitis), ‘mm’ (mesangial matrix increase), and 
‘cg’ (transplant glomerulopathy). Those for tubules are 
‘t’ (tubulitis) and ‘ct’ (tubular atrophy), while for intersti-
tium, they are ‘i’ (interstitial inflammation) and ‘ci’ (in-
terstitial fibrosis). The ‘ti’ and ‘i-IFTA (interstitial fibrosis 
and tubular atrophy)’ characters, which indicate tubu-
lointerstitial inflammation, were added in Banff 2007 and 
Banff 2015, respectively. ‘ti’ is defined as inflammation 
in total parenchyma, including scarred and non-scarred 
cortex [13], whereas ‘i-IFTA’ is defined as inflammation 
in areas of tubular atrophy and interstitial fibrosis [17].
For vessels, ‘v’ (intimal arteritis) and ‘cv’ (arterial fi-
brous intimal thickening) describe arteries, and ‘ah’ and 
‘aah’ indicate hyaline arteriolar thickening [13]. In par-
ticular, although ‘aah’ was added to specifically address 
calcineurin inhibitor-related arteriolopathy, its specific-
ity has not yet been verified. Two PTC criteria, ‘ptc’ and 
‘C4d’, were added in Banff 2003 [11] and Banff 2001 [10], 
respectively, and refined in Banff 2007 [13]. ‘Ptc’ denotes 
peritubular capillaritis. ‘C4d’ is determined by either im-
munofluorescence or immunohistochemical methods, 
with different standards for positivity [13].
The Banff scoring system has three grades: mild (1), 
moderate (2), and severe (3). The cut-off points for ‘g’, 
‘cg’, ‘mm’, ‘ct’, ‘i’, and ‘ci’ scores are < 25%, 25% to 50%, 
and > 50%. However, the cut-off points for ‘i’ are 10% to 
25%, 25% to 50%, and > 50%, and for ‘ci’ they are 5% to 
25%, 25% to 50%, and > 50%. Cut-off point for ‘t’ and ‘ptc’ 
scores are < 4, 4 to 10, and > 10 inflammatory cells/tubule 
or PTC [11,13]. Scores for ‘v’ are dependent on the extent 
of vascular wall involvement (< 25% intima, > 25% in-
tima, and medial involvement), and for ‘cv’, they are de-
pendent on the percentage of luminal narrowing (< 25%, 
25% to 50%, and > 50%). Scores for ‘ah’ are dependent on 
the number and severity of hyalinosis. An asterisk (*) is 
added to express the type of inflammatory cells (‘i’, ‘ptc’), 
the presence of interstitial hemorrhage or infarction (‘v’), 
or arteriolitis (‘ah’) [27].
Table 1. Banff diagnostic categories (modified from reference [27])
Category 1 Normal biopsy or non-specific changes
Category 2 Antibody-mediated changes
Category 3 Suspicious (borderline) for acute T cell-mediated rejection
Category 4 T cell-mediated rejection
Category 5 Interstitial fibrosis and tubular atrophy
Category 6 Other non-rejection changes
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Antibody-mediated rejection 
Diagnosis of active and chronic ABMR requires the 
presence of morphologic, immunohistologic, and sero-
logic evidence. The morphologic features suggestive of 
active and chronic injury are unique, but active injury 
may coexist in chronic active ABMR. In contrast, the im-
munohistologic and serologic indicators are the same for 
active and chronic ABMR (Table 2) [27].
Although C4d was believed to be a distinct immunohis-
tologic marker for ABMR [10,12], it was later recognized 
that C4d deposition can be present without morphologic 
evidence of active rejection [13], and C4d may be absent 
in ABMR [15,16]. Furthermore, donor-specific antibody 
(DSA) is not always detected in ABMR [28,29]. There-
fore, ‘Increased expression of gene transcripts/classifiers 
strongly associated with ABMR’ was included as an alter-
native to C4d positivity in Banff 2017 [18].
The inclusion of ancillary molecular markers for diag-
nosis/differential diagnosis of ABMR has been supported 
by several reports that have described discrepancies be-
tween clinical, immunologic, and pathologic findings, as 
well as by the limitations of biopsy interpretation [30,31]. 
Sellarés et al [32] reported that microarray assessment 
of endothelial cells or NK gene expression was helpful 
in the diagnosis of ABMR. O'Connell et al [33], Modena 
et al [34], and Halloran et al [35] also showed benefits of 
gene expression profiling in the diagnosis of ABMR and 
identification of patients at risk of chronic injury. In ad-
dition, Reeve et al [36] demonstrated better prediction of 
graft survival from molecular scores than from histologic 
diagnoses.
T cell-mediated rejection 
The diagnosis of acute and chronic TCMR largely de-
pends on morphologic changes in the tubulointerstitial 
compartment. Diagnostic criteria for acute TCMR have 
not changed significantly since Banff 1991, and are graded 
according to active inflammation of non-atrophic tubules 
and interstitium and vessels. However, the criteria for 
chronic active TCMR were updated in Banff 2017 (Table 3) 
[27]. To diagnose chronic active TCMR, tubulointerstitial 
inflammation with a score > 2 should be present in areas 
of atrophic tubules and interstitial fibrosis, as well as in 
non-scarred tubules and interstitium [18,37-39].
Other revisions and Banff working groups
The term ‘CAN’ (chronic allograft nephropathy) was 
used to describe tubular atrophy and interstitial fibrosis, 
regardless of the underlying pathogenetic mechanisms, 
in the initial Banff 1991 report [8]. However, this term is 
problematic due to the fact that both rejections and non-
Table 2. Antibody-mediated rejection (modified from reference [27])
Morphologic Immunologic Serologic
Acute ABMR Microvascular inflammation (g > 0 and/or ptc >0) Linear C4d staining in PTCs DSAs
Intimal or transmural arteritis (v >0) At least moderate microvascular inflammation ([g + ptc] ≥ 2)
Acute TMA in the absence of any other cause Increased expression of gene transcripts in biopsy tissue 
indicative of endothelial injury
Acute tubular injury in the absence of any other 
apparent cause
Chronic active  
ABMR
TG (cg > 0), if no evidence of chronic TMA Linear C4d staining in PTCs DSAs
Severe PTC basement membrane multilayering At least moderate microvascular inflammation ([g + ptc] ≥ 2)
Arterial intimal fibrosis of new onset, excluding  
other causes
Increased expression of gene transcripts in the biopsy 
tissue indicative of endothelial injury
Chronic ABMR TG (cg > 0), if no evidence of chronic TMA A prior documented diagnosis of active or chronic active 
ABMR
DSAs
Severe PTC basement membrane multilayering
Arterial intimal fibrosis of new onset, excluding  
other causes
ABMR, antibody-mediated rejection; cg, transplant glomerulopathy; DSA, donor-specific antibody; g, glomerulitis; PTC, peritubular capillary; TMA, thrombotic 
microangiopathy; v, intimal arteritis.
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rejections are included within the same group. It was 
therefore eliminated in Banff 2005 and replaced by spe-
cific diagnosis or the non-specific term ‘IFTA’ (interstitial 
fibrosis and tubular atrophy) [12].
Specialized Banff working groups have been convened 
to address issues relating to problematic areas in biopsy 
interpretation. The first working groups were organized 
at the Banff 2009 meeting, and these focused on ‘Isolated 
v-lesion’, ‘Fibrosis scoring’, ‘Polyoma virus nephropathy 
staging’, ‘Glomerular lesion scoring’, ‘Molecular pathol-
ogy’, and ‘Quality assurance’ [14]. At the Banff 2011 and 
Banff 2013 meetings, the ‘C4d-Banff initiative for quality 
assurance in transplantation’ (BIFQUIT), ‘BK-BIFQUIT’, 
‘Implantation biopsies’, ‘C4d-negative ABMR’, ‘TCMR’, 
‘Clinical and laboratory assessment of highly sensitized 
patients’, and ‘Evaluation of adjunctive diagnostics in re-
nal allograft biopsy interpretation’ groups were formed 
[15,16]. Working groups on ‘Electron microscopy’, ‘TMA’, 
‘Recurrent glomerular disease’, ‘Composite surrogate end 
points’, ‘HIV+/HIV+ renal transplants’, and ‘Banff rules 
and dissemination’ were newly formed at the Banff 2015 
and Banff 2017 meetings [17,18]. Several reports have 
been published from the working groups [40-42], and 
their efforts have been reflected in Banff updates.
Pitfalls of the current Banff classification
Although significant progress has been made in our 
understanding of rejection pathogenesis and in the re-
finement of morphologic and laboratory criteria for Banff 
classification, a number of uncertainties and drawbacks 
remain. These will be discussed in the following sections.
Criteria for quantitative scoring
In the Banff classification, glomerulitis is defined as 
endothelial cell enlargement along with the presence of 
inflammatory cells and capillary occlusion of ≥ 1 capil-
lary loops. However, the number of inflammatory cells 
and minimum threshold for near-occlusion have not 
been clarified [43]. In addition, endothelial enlargement 
is subjective, and therefore, a mild degree of endothelial 
activation may not be recognized.
Presently, borderline changes are ‘suspicious’ for acute 
TCMR. The criteria for diagnosis of tubulitis and intersti-
tial inflammation have also been changed at a number of 
meetings, resulting in confusion and inconsistent com-
munication. For example, at Banff 2001, the criteria were 
‘t1 and at least i1’. At Banff 2005 they were changed to ‘t1, 
t2, or t3 with i0 or i1’, and at Banff 2007, they were modi-
fied again to ‘t1, t2, or t3 with i0 or i1’ or ‘i2 or i3 with t1’. 
Finally, at Banff 2017, the criteria for tubulitis and inter-
stitial inflammation were established as ‘t > 0 with i0 or 
i1’ or ‘i2 or i3 with t1’. In a recent report on borderline 
changes, these inconsistences have resulted in heteroge-
neous diagnostic groups [44].
Another parameter that may be considered for adjust-
ment is PTCBML. This was defined as ≥ 7 PTC basement 
membrane layers in ≥ 1 PTC, or 5 to 6 layers in ≥ 3 PTCs. 
Table 3. T cell-mediated rejection (modified from reference [27])
Description Banff scores
Acute TCMR
   Type IA Moderate tubulitis and at least moderate interstitial inflammation t2i2 or t2i3
   Type IB Severe tubulitis and at least moderate interstitial inflammation t3i2 or t3i3
   Type IIA Mild to moderate intimal arteritis v1
   Type IIB Severe intimal arteritis (> 25% of the luminal area) v2
   Type III ‘Transmural’ arteritis and/or fibrinoid necrosis v3
Chronic active TCMR
   Grade IA Moderate tubulitis and at least moderate total cortical inflammation and at least moderate  
scarred cortical inflammation and other known causes ruled out
t2, ti ≥ 2, and 
i-IFTA ≥ 2
   Grade IB Severe tubulitis and at least moderate total cortical inflammation and at least moderate  
scarred cortical inflammation and other known causes ruled out
t3, ti ≥ 2, and 
i-IFTA ≥ 2
   Grade II Arterial intimal fibrosis with mononuclear cell inflammation, formation of neointima cv1, cv2, or cv3
cv, arterial fibrous intimal thickening; i, interstitial inflammation; i-IFTA, tubulointerstitial inflammation (inflammation in areas of interstitial fibrosis and tubular 
atrophy); t, tubulitis; TCMR, T cell-mediated rejection; ti, tubulointerstitial inflammation (inflammation in total parenchyma, including scarred and non-scarred cortex); v, 
intimal arteritis.
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However, the minimum numbers and cut-off values of 
PTCBML are difficult to determine in daily practice [45]. 
Furthermore, electron microscopy, which is required for 
accurate diagnosis, is not available in many transplant 
centers.
Non-rejection conditions
Non-rejection conditions/diseases are grouped in Banff 
category 6 as a separate sheet [8]. However, with increas-
ing graft survival, there have been increased opportuni-
ties to observe these conditions in late post-transplant 
biopsies, and they are often associated with graft dys-
function. For example, development of massive crescents 
in post-transplant IgA nephropathy or recurrent anti-
neutrophil cytoplasmic antibody-associated glomerulo-
nephritis may be a major contributor to graft dysfunction 
[46-48]. Additionally, recurrent focal segmental glomer-
ulosclerosis can cause massive proteinuria. Therefore, 
integrated evaluation and interpretation of dominant 
injury patterns are required, particularly in cases with 
combined non-rejection conditions/diseases and rejec-
tions. Further, ‘g’, ‘cg’, and ‘mm’ scores are used in the 
classification of both rejection and glomerular diseases 
[49,50], but scores for crescents and global and segmental 
sclerosis, which are useful in the evaluation of glomeru-
lar diseases, are not included in the Banff parameters.
Uncertain pathogenesis for similar morphologies
The histology of intimal arteritis and transplant ar-
teriopathy is rather distinct. However, it is difficult to 
determine whether the development of intimal arteritis 
and transplant arteriopathy is associated with cell or 
antibody-mediated mechanisms or if these conditions 
arose with or without rejection. One morphologic clue is 
the presence of other known features of TCMR or ABMR; 
however, this does not apply in cases of isolated vascu-
litis. Notably, inflammatory cell phenotyping in isolated 
vasculitis has revealed heterogeneity [51-53], which may 
reflect distinct injury mechanisms.
The observation of ‘C4d-positive renal transplant biop-
sies without evidence of rejection’ is also associated with 
uncertainty. Intriguingly, one study performed gene ex-
pression analysis and identified patients at higher risk of 
developing ABMR among these cases [54].
Others
In the current Banff classification, interstitial inflam-
mation is defined by its extent. However, there is no way 
to determine whether inflammatory cells are active or 
quiescent or if their composition is related to inflamma-
tory activity or fibrosis. Further, asterisks in some Banff 
scores, some related to inflammatory subtypes, are not 
popular, and their significance is not known.
Future perspectives
The discovery and application of non-invasive molecu-
lar markers for effective diagnosis of renal transplant re-
jection are active fields of research [55-57]. Importantly, 
to develop a comprehensive approach, integration of 
tissue pathology assessment, transcriptomics, and uri-
nary proteomics may be needed, particularly in cases 
of chronic TCMR [58]. Recently, the NanoString Banff 
consortium was launched to develop the nCounter Hu-
man Organ Transplant Panel to identify biomarkers of 
rejection, uncover the mechanisms behind tissue dam-
age, and monitor immunosuppressive drug toxicity and 
infections using paraffin-embedded renal tissue [59]. 
Diagnosis of mixed rejection and the often problematic 
coexistence of polyomavirus nephropathy and rejection 
or calcineurin inhibitor toxicity and rejection may benefit 
from this approach. Furthermore, clinical significance of 
antibody responses to non-HLA antigens, such as major 
histocompatibility complex class I chain-related proteins 
A and B and angiotensin II type 1 receptor, may be clari-
fied [60,61].
Immunophenotyping of allograft biopsies may also pro-
vide some additional benefits, for example facilitating the 
detection of glomerulitis. In particular, this strategy may 
help us to understand and distinguish the inflamma-
tory and profibrotic phases of inflammation and/or the 
activity of inflammation. To this end, multiplex immuno-
histochemistry is likely to be especially useful, as inflam-
matory cells are mixed in nature and vary throughout the 
rejection process [62-64]. Digital pathology has become 
increasingly popular in pathology practice, both in clini-
cal biopsy diagnosis and in research. This strategy has the 
potential to reduce inter-observer variation and increase 
objectivity through use of quantification. For example, 
interstitial inflammatory phenotypes have been reported 
from digitization of immunostained biopsy sections and 
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algorithm-driven analysis, with good clinical correlation 
[65]. Deep learning-based histopathological assessment 
of transplant biopsies [66] has also been performed, and 
high correlations between the neural network’s quanti-
fication of glomeruli, interstitium, and atrophic tubules 
and results from renal pathologists were reported.
As noted previously, addition of scores for crescents 
and global and segmental sclerosis to the current Banff 
scores is necessary for integrated evaluation of biopsies 
from patients with combined non-rejection conditions/
diseases and rejections.
Lastly, with recent advances in bioengineered organs, 
we may also need to implement strategies to deal with 
abnormalities in bioengineered organs. Recently, Solez et 
al [67] proposed the construction of a framework for the 
classification of tissue engineering pathology at future 
Banff Transplant Pathology meetings, in collaboration 
with the Human Cell Atlas project [68].
To summarize, for precision diagnosis of transplant 
rejection, integration of histological, laboratory, and 
tailored molecular markers is necessary. Artificial-
intelligence based assistance has the potential to further 
improve diagnostic accuracy.
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